Annual Report 2016 Company Announcement No. 11/2017 – 8

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
112
Annual Report 2016

Company Announcement No. 11/2017 – 8 March 2017

Annual Report 2016

Strategy delivers earnings increase once again based on entrepreneurship, commercial focus and high efficiency 

  • Record-high earnings and earnings per share
  • Royal Unibrew generally maintained its market shares in 2016
  • Sales went up by 6% and net revenue by 5%
  • EBITDA showed a DKK 81 million increase to DKK 1,306 million
  • EBIT showed a DKK 84 million increase to DKK 1,001 million, and EBIT margin showed a 0.6 percentage point increase to 15.8%
  • Free cash flow amounted to DKK 1,022 million, representing 16% of net revenue
  • DKK 829 million was distributed to the shareholders in 2016
  • It has been decided to launch as soon as possible a share buy-back programme of DKK 560 million
  • The Board of Directors proposes the distribution of dividend of DKK 8.15 per share, corresponding to a total of DKK 441 million
  • Jesper B. Jørgensen will join as new CEO on 1 April 2017

"2016 was yet another good year for Royal Unibrew. Despite challenging market conditions in several of our markets, our earnings continued to increase, which should be viewed in light of, not least, many innovative measures across our organisation and our local presence with our consumers and customers. In recent years, we have focused intensively on developing the craft beer market, launching many exciting, new products which have been received well by our consumers - and in 2017 we will open our craft beer brewery in Denmark. As a result of the earnings improvement combined with our outlook for the years ahead, we are increasing our medium-term EBIT target from about 15% to about 16%. At the same time, we are increasing distributions to DKK 1 billion as a combination of a higher dividend and the most extensive share buy-back programme in our history" says Henrik Brandt, CEO.

Selected Financial Highlights and Ratios         Q1-Q4 Q4
MDKK   2016 2015   2016 2015
Sales (thousand hectolitres)   9,678 9,100   2,221 2,236
Net revenue   6,340 6,032   1,466 1,423
EBITDA   1,306 1,225   254 223
EBITDA-margin (%) Earnings before interest and tax (EBIT)   20.6 1,001 20.3 917   17.3 175 15.7 142
EBIT-margin (%)   15.8 15.2   12.0 10.1
Proft before tax   998 902   179 146
Net profit for the year   784 711   143 123
Free cash flow   1,022 1,032   187 239
             
MDKK   Q4 2016 Q4 2015 Q4 2014 Q4 2013  
Net interesting-bearing debt   991 1,184 1,553 2,379  
NIBD/EBITDA (current 12 months)   0.8 1.0 1.4 2.3*  
Equity ratio (%)   48 43 40 31  

 * calculated proforma with Hartwall’s realised full-year EBITDA

Outlook for 2017

           
    Forventet Realiseret Realiseret  
MDKK   2017 2016 2015  
Net revenue   6,250-6,450 6,340 6,032  
EBITDA   1,285-1,385 1,306 1,225  
EBIT   980-1,080 1,001 917  

The Annual Report has been published via Nasdaq Copenhagen A/S and is enclosed with this announcement.

The Annual report is also available on www.royalunibrew.com.

For further information on this announcement:

Henrik Brandt, CEO, tel. +45 22 20 80 17.

 

It will be possible for investors and analysts to follow Royal Unibrew’s presentation of the Annual Report on Thursday, 9 March 2017, at 9 am by audiocast at one of the following dial-in numbers

Denmark:  +4532 71 16 60

United Kingdom:  +44(0)20 3427 1913

United States of America:  +1212 444 0896

Financial Calendar 2017

27 April 2017              Interim Report for the period 1 January – 31 March 2017

27 April 2017              Annual General Meeting at Ceres Park & Arena i Aarhus

21 August 2017          Interim Report for the period 1 January – 30 June 2017

22 November 2017    Interim Report for the period 1 January – 30 September 2017  

Disclaimer

This announcement contains forward-looking statements, including statements about the Group’s sales, revenues, earnings, spending, margins, cash flow, inventory, products, actions, plans, strategies, objectives and guidance with respect to the Group’s future operating results. Forward-looking statements include, without limitation, any statement that may predict, forecast, indicate or imply future results, performance or achievements, and may contain the following words or phrases “believe, anticipate, expect, estimate, intend, plan, project, will be, will continue, likely to result, could, may, might”, or any variations of such words or other words with similar meanings. Any such statements involve known and unknown risks, estimates, assumptions and uncertainties that could cause the Group’s actual results, performance, or industry results to differ materially from the results expressed or implied in such forward-looking statements. The Group assumes no obligation to update any such forward-looking statements to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking statements.

Some important risk factors that may have direct bearing on the Group’s actual results include, but are not limited to: economic and political uncertainty (including interest rates and exchange rates), financial and regulatory developments, development in the demand for the Group’s products, introduction of and demand for new products, the competitive environment and the industry in which the Group operates, changes in consumer preferences, increasing industry consolidation, the availability and pricing of raw materials and packaging materials, cost of energy, production- and distribution-related issues, information technology failures, breach or unexpected termination of contracts, price reductions resulting from market-driven price reductions, determination of fair value in the opening balance sheet of acquired entities, litigation, environmental issues and other unforeseen factors.

New risk factors can emerge in the future, which the Group cannot predict. Furthermore, the Group cannot assess the impact of each factor on the Group’s business or the extent to which any individual risk factor, or combination of factors, may cause results to differ materially from those contained in any forward-looking statement. Accordingly, forward-looking statements should not be relied on as a prediction of actual results.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Updated Category News Views 3

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 3

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 5

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 5

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 6

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading

Top 5 Most Recently Viewed Articles

XPENG Delivers 39,107 Vehicles in August 2026

Updated Category News Views 11

Grit and Green in XPENG's Latest Numbers You'd think someone at XPENG's HQ popped the champagne today, given what they're reporting, but don't let the buzz fool you. August 2026 saw them deliver 39,107 vehicles. That's a nice 4% tick up year over year. But remember, we're talking a sector where anything short of double digits can feel like a whisper instead of a roar....

Continue Reading
Artivion Set to Announce Financial Results in February 2026

Updated Category News Views 90

Artivion to Announce Fourth Quarter Financial Results Artivion, Inc. (NYSE: AORT), a renowned company in the cardiac and vascular sector, has set a date for the release of its fourth quarter financial results for the year 2025. The main announcement will occur on the afternoon of the market closing on February 12, 2026. This release is highly anticipated within investor...

Continue Reading
FibroBiologics and Charles River Unite for Cell Therapy Advancements

Updated Category News Views 181

FibroBiologics Partners with Charles River for Innovative Therapies FibroBiologics, Inc. (Nasdaq: FBLG), a pioneering biotechnology company, has announced a groundbreaking collaboration with Charles River Laboratories, a renowned name in drug discovery and manufacturing. This partnership aims to develop and manufacture advanced fibroblast cell-based therapies intended to...

Continue Reading
Axsome Therapeutics Looks Ahead with Participations in Events

Updated Category News Views 128

Axsome Therapeutics: Engaging the Investment Community Axsome Therapeutics, Inc. (NASDAQ: AXSM), a pioneering biopharmaceutical enterprise focused on revolutionary treatments for central nervous system (CNS) disorders, has exciting plans ahead as it prepares to engage with investors at significant upcoming conferences. This engagement highlights the company's commitment...

Continue Reading
Palmstreet's Bold Moves in the $68B Live Shopping Boom

Updated Category News Views 9

Palmstreet Sets the Stage for Seller Success As the live shopping phenomenon in the U.S. rivals the busiest stock market scramble, Palmstreet is laying down some serious game-changing strategies. We're staring at a market expected to hit a staggering $68 billion in 2026, more than doubling its size from three years ago. Instead of riding the coattails of this lucrative...

Continue Reading